Dr. Colm Henry:

Based on the returns in respect of the 700,000 doses, we see they have largely been confined to the priority groups. Some 400,000 have been given to the over-65s, 35,000 to healthcare workers, 323,000 to 18- to 64-year-olds in at-risk groups, and there is the addition of the new, nasal vaccine to children. Based on patterns to date, it appears the strong message we have been giving repeatedly to pharmacists and GPs to confine the vaccine to priority groups seems to have been adhered to.